Latest News-Insilico Medicine Mediaroom_Page

Insilico Medicine Announces Global R&D Collaboration with Lilly

AI-driven collaboration includes an exclusive worldwide license for a portfolio of programs spannin...

2026-03-30 08:30 4206

Insilico Medicine and Tenacia Biotechnology Expand AI-Driven CNS Collaboration with Deal Value Up to US$94.75 Million

CAMBRIDGE, Mass., March 26, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinica...

2026-03-26 22:08 4929

Insilico Medicine and ASKA Pharmaceutical Expand Partnership to Discover Novel Targets for Women's Health

CAMBRIDGE, Mass., March 24, 2026 /PRNewswire/ -- Insilico Medicine (3696.HK), a clinical-stage drug...

2026-03-24 18:29 2893

Insilico Medicine Launches PandaClaw: Empowering Biologists with Agentic AI for Therapeutic Discovery

CAMBRIDGE, Mass., March 23, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage g...

2026-03-23 20:30 4499

Insilico Medicine to Announce 2025 Financial Results on March 30, 2026

CAMBRIDGE, Mass., March 13, 2026 /PRNewswire/ -- Insilico Medicine (HKEX: 3696.HK, "Insilico" or th...

2026-03-13 21:59 9097

Insilico and TaiGen Achieve Milestone in Collaboration: Out-Licensed CKD Anemia Candidate ISM4808 Completes first human enrollment and dosing in Phase I clinical trial

CAMBRIDGE, Mass., March 5, 2026 /PRNewswire/ -- Insilico Medicine (Insilico Medicine, HKEX: 03696),...

2026-03-06 18:53 5666

Insilico Medicine and Liquid AI Announce Strategic Partnership Delivering Lightweight Scientific Foundation Models for Drug Discovery

Single 2.6B-parameter model achieves state-of-the-art performance across drug discovery benchmarks ...

2026-03-03 22:25 5848

Insilico Medicine and Liquid AI Announce Strategic Partnership Delivering Lightweight Scientific Foundation Models for Drug Discovery

AI-Powered R&D Acceleration: Insilico Medicine and CMS announce multiple collaborations in central nervous system and autoimmune diseases

CAMBRIDGE, Mass., Feb. 10, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinica...

2026-02-10 21:00 7545

Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development - Oncology

CAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico") (3696.HK), a clinic...

2026-02-06 21:00 8420

Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications

* NLRP3 is a validated anti-inflammatory target that mediates the release of proinflammatory cyto...

2026-02-05 21:00 7899

Insilico Medicine Receives USD 5million Milestone Payment from Menarini Group Following First-in-Human (FIH) Achievement for MEN2501

Followed by the development and regulatory milestone payment of USD 3 million in July 2025, Insilic...

2026-02-03 22:00 7420

Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies

CAMBRIDGE, Mass., Jan. 27, 2026 /PRNewswire/ -- Insilico Medicine, a clinical-stage biotechnology c...

2026-01-27 22:00 8415

Insilico Medicine Receives IND Approval from FDA for ISM8969, an AI-empowered Potential Best-in-class NLRP3 Inhibitor

* Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) paves ...

2026-01-23 21:30 14350

Insilico Medicine Launches Science MMAI Gym to Transform Frontier LLMs into Pharmaceutical-Grade Scientific Engines

* New "AI GYM for Science" dramatically boosts the biological and chemical intelligence of any ca...

2026-01-22 22:37 9201

Insilico Medicine and Hygtia Therapeutics Enter New Global Strategic Collaboration to Co-Develop Novel Brain Penetrant NLRP3 Inhibitor for CNS Diseases treatment

* Insilico Medicine and Hygtia Therapeutics, an incubatee of Shenzhen Pengfu Fund of Fosun Health...

2026-01-21 08:15 7359

Insilico Medicine Completes First Patient First Dose in BETHESDA: A Phase II Trial for Garutadustat (ISM5411), the Gut-restricted AI-driven PHD Inhibitor for the Treatment of Inflammatory Bowel Disease

CAMBRIDGE, Mass., Jan. 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage, g...

2026-01-12 21:30 1674

Insilico Medicine Announce US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology

* Insilico Medicine achieved an R&D collaboration with Servier valued at up to US$888 million, fo...

2026-01-05 08:30 4925

Insilico Medicine Lists on Hong Kong Stock Exchange, Showing AI Drug Discovery Momentum with 2025's Largest Hong Kong Biotech IPO

HONG KONG, Dec. 30, 2025 /PRNewswire/ -- Insilico Medicine (3696.HK), a clinical-stage drug discove...

2025-12-30 17:00 12861

Insilico Medicine Lists on Hong Kong Stock Exchange, Showing AI Drug Discovery Momentum with 2025's Largest Hong Kong Biotech IPO

Insilico Medicine and TaiGen Achieves License Agreement to Develop and Commercialize AI-driven PHD Inhibitor for Anemia of Chronic Kidney Disease (CKD)

* Insilico Medicine has licensed TaiGen Biotechnology exclusive rights in the Greater China area ...

2025-12-12 20:00 3825

Nature Communications | Insilico Medicine Presents AI-empowered Dual-Action PROTAC Targeting PKMYT1

* AI Designs a Novel RPOTAC from Scratch: Insilico's generative AI platform, Chemistry42, success...

2025-12-02 22:00 2781